The status of naltrexone in the treatment of alcohol dependence: Specific effects on heavy drinking

Journal of Clinical Psychopharmacology

Volumn 26, Issue 6, 2006, Pages 610-625

  Pettinati, Helen M ^a   O'Brien, Charles P ^a,b   Rabinowitz, Amanda R ^a   Wortman, Shoshana P ^a   Oslin, David W ^a,b   Kampman, Kyle M ^a   Dackis, Charles A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; DISULFIRAM; LIVER ENZYME; NALTREXONE; OPIATE ANTAGONIST; SERTRALINE;

ABSTINENCE; ALCOHOLISM; ALERTNESS; ANXIETY; ATTENTION DISTURBANCE; CLINICAL TRIAL; DEPRESSION; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DYSPHORIA; ENERGY BALANCE; FOOD AND DRUG ADMINISTRATION; HUMAN; LIVER CELL DAMAGE; LIVER TOXICITY; MEDLINE; META ANALYSIS; MOOD CHANGE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALCOHOL DRINKING; ALCOHOLISM; DOUBLE-BLIND METHOD; HISTORY, 20TH CENTURY; HUMANS; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 33751087769     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000245566.52401.20     Document Type: Review

References (107)

1. O'Brien CP, Pettinati HM, Oslin DW. Naltrexone: clinical data. In: Spanagel R, Mann K, eds. Drugs for Relapse Prevention of Alcoholism. Basel, Switzerland: Birkhäuser Verlag; 2005:59-72.
2. Mark TL, Kranzler HR, Poole VH, et al. Barriers to the use of medications to treat alcoholism. Am J Addict. 2003;12(4):281-294.
3. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-2017.
4. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA. 1999;281(14):1381-1325.
5. Kranzler HR. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol. 2000;35(6):537-547.
6. Melchior JA, Hoes JM. Relapse prevention in alcoholics: a review of acamprosate versus naltrexone. Clin Drug Invest. 1999;17:211-216.
7. Modesto-Lowe V, Van Kirk J. Clinical uses of naltrexone: a review of the evidence. Exp Clin Psychopharmacol. 2002;10(3):213-227.
8. Moncrieff J, Drummond DC. New drug treatments for alcohol problems: a critical appraisal. Addiction. 1997;92(8):939-957.
9. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25(9):1335-1341.
10. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. 2001;36(6):544-552.
11. Krystal JH, Cramer JA, Krol WF, et al. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345(24):1734-1739.
12. Volpicelli JR, Rhines KC, Rhines JS, et al. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry. 1997;54(8):737-742.
13. Chick J, Anton RF, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35(6):587-593.
14. Monti PM, Rohsenow DJ, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res. 2001;25(11):1634-1647.
15. Pettinati HM, Volpicelli JR, Pierce JDJ, et al. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis. 2000;19(1):71-83.
16. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28:1546-1552.
17. Gianoulakis C, Béliveau D, Angelogianni P, et al. Different pituitary beta-endorphin and adrenal cortisol response to ethanol in individuals with high and low risk for future development of alcoholism. Life Sci. 1989;45(12):1097-1109.
18. Jaffe AJ, Rounsaville B, Chang G, et al. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol. 1996;64(5):1044-1053.
19. King AC, Schluger J, Gunduz M, et al. Hypothalamic-pituitary- adrenocortical (HPA) axis response and biotransformation of oral naltrexone: preliminary examination of relationship to family history of alcoholism. Neuropsychopharmacology. 2002;26(6):778-788.
20. Monterosso JR, Flannery BA, Pettinati HM, et al. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict. 2001;10:258-268.
21. King AC, Volpicelli JR, Frazer A, et al. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology. 1997;129:15-22.
22. Altshuler HL, Phillips PE, Feinhandler DA. Alteration of ethanol self-administration by naltrexone. Life Sci. 1980;26(9):679-688.
23. Harris RA, Erickson CK. Alteration of ethanol effects by opiate antagonists. Curr Alcohol. 1979;5:17-28.
24. Marfaing-Jallet P, Miceli D, Le Magnen J. Decrease in ethanol consumption by naloxone in naive and dependent rats. Pharmacol Biochem Behav. 1983;18(suppl 1):537-539.
25. Froehlich JC, Harts J, Lumeng L, et al. Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol Biochem Behav. 1990;35:385-390.
26. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876-880.
27. Volpicelli JR, O'Brien CP, Alterman AI, et al. Naltrexone and the treatment of alcohol dependence: initial observations. In: Reid LD, ed. Opioids, Bulimia, and Alcohol Abuse & Alcoholism. New York: Springer-Verlag; 1990:195-214.
28. O'Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49(11):881-887.
29. Volpicelli JR, Watson NT, King AC, et al. Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry. 1995;152(4):613-615.
30. Fuller RK, Branchery L, Brightwell DR, et al. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA. 1986;256:1449-1455.
31. Beakeland F, Lundwall L, Kissin B, et al. The correlates of outcome in disulfiram treatment of alcoholism. J Nerv Ment Dis. 1971;53:1-9.
32. Paille F, Guelfi J, Perkins A, et al. Double-blind, randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30(2):239-247.
33. Pelc I, Verbanck P, LeBon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. Br J Psychiatry. 1997;171:73-77.
34. Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53:673-680.
35. Paille FM, Guelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30(2):239-247.
36. Pelc I, Verbanck P, Le Bon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997;171:73-77.
37. Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53(8):673-680.
38. Brewer C. Controlled trials of antabuse in alcoholism: the importance of supervision and adequate dosage. Acta Psychiatr Scand Suppl. 1992;369:51-58.
39. Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today. Addiction. 2004;99:21-24.
40. Suh JJ, Pettinati HM, Kampman KM, et al. The status of disulfiram: a half of a century later. J Clin Psychopharmacol. 2006;23(3):290-302.
41. De Witte P, Littleton J, Parot P, et al. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs. 2005;19(6):517-537. [review]
42. Heinz A, Mann K, Weinberger DR, et al. Serotonergic dysfunction, negative mood states, and response to alcohol. Alcohol Clin Exp Res. 2001;25(4):485-486.
43. Kranzler HR, Anton RF. Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism. J Consult Clin Psychol. 1994;62(6):1116-1126.
44. McLellan AT, Lewis DC, O'Brien CP, et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689-1685.
45. Imperato A, Di Chiara G. Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther. 1986;239(1):219-228.
46. Wise RA. The neurobiology of craving: implications for the understanding and treatment of addiction. J Abnorm Psychol. 1988;97(2):118-132.
47. Mereu G, Fadda F, Gessa GL. Ethanol stimulates the firing rate of nigral dopaminergic neurons in unanesthetized rats. Brain Res. 1984;292(1):63-69.
48. Koob GF, Weiss F. Neuropharmacology of cocaine and ethonol dependence. Recent Dev Alcohol. 1992;10:201-233.
49. Ohara H, Miyabi Y, Deyashiki Y, et al. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem Pharmacol. 1995;50(2):221-227.
50. Stromberg MF, Rukstalis MR, Mackler SA, et al. A comparison of the effects of 6-beta naltrexol and naltrexone on the consumption of ethanol or sucrose using a limited-access procedure in rats. Pharmacol Biochem Behav. 2002;72(1-2):483-490.
51. Verebey K, Volavka J, Mule SJ, et al. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther. 1976;20(3):315-328.
52. Lee MC, Wagner HN, Tanada S, et al. Duration of occupancy of opiate receptors by naltrexone. J Nuclear Med. 1988;29(7):1207-1211.
53. Swift RM, Whelihan W, Kuznetsov O, et al. Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry. 1994;151(10):1463-1467.
54. McCaul ME, Wand GS, Eissenberg T, et al. Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropsychopharmacology. 2000;22(5):480-492.
55. O'Malley SS, Jaffe AJ, Chang G, et al. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry. 1996;53(3):217-224.
56. Reisine T, Law SF, Blake A, et al. Molecular mechanisms of opiate receptor coupling to G proteins and effector systems. Ann N Y Acad Sci. 1996;780:168-175.
57. Kleber HD, Kosten TR, Gaspari J, et al. Nontolerance to the opioid antagonism of naltrexone. Biol Psychiatry. 1985;20(1):66-72.
58. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry. 1997;54(12):1130-1135.
59. Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 1988;35(3):192-213.
60. Mendelson JH, Ellingboe J, Kuehnle JC, et al. Heroin and naltrexone effects on pituitary-gonadal hormones in man: interaction of steroid feedback effects, tolerance and supersensitivity. J Pharmacol Exp Ther. 1980;214(3):503-506.
61. Crowley TJ, Wagner JE, Zerbe G, et al. Naltrexone-induced dysphoria in former opioid addicts. Am J Psychiatry. 1985;142(9):1081-1084.
62. Malcolm R, O'Neil PM, Von JM, et al. Naltrexone and dysphoria: a double-blind placebo controlled trial. Biol Psychiatry. 1987;22(6):710-716.
63. Brahen LS, Capone TJ, Capone DM. Naltrexone: lack of effect on hepatic enzymes. J Clin Pharmacol. 1988;28(1):64-70.
64. Greenstein RA, Resnick RB, Resnick E. Methadone and naltrexone in the treatment of heroin dependence. Psychiatr Clin North Am. 1984;7(4):671-679.
65. Mitchell JE, Morley JE, Levine AS, et al. High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry. 1987;22(1):35-42.
66. Malcolm R, O'Neil PM, Sexauer JD, et al. A controlled trial of naltrexone in obese humans. Int J Obes. 1985;9(5):347-353.
67. Atkinson RL, Berke LK, Drake CR, et al. Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther. 1985;38(4):419-422.
68. Pfohl DN, Allen JI, Atkinson RL, et al. Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. NIDA Res Monogr. 1986;67:66-72.
69. Berg BJ, Pettinati HM, Volpicelli JR. A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Drug Saf. 1996;15(4):274-282.
70. Marrazzi MA, Kinzie J, Luby ED. A detailed longitudinal analysis on the use of naltrexone in the treatment of bulimia. Int Clin Psychopharmacol. 1995;10(3):173-176.
71. Gillberg C. Endogenous opioids and opiate antagonists in autism: brief review of empirical findings and implications for clinicians. Dev Med Child Neurol. 1995;37(3):239-245.
72. Willemsen-Swinkels SH, Buitelaar JK, Nijhof GJ, et al. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Arch Gen Psychiatry. 1995;52(9):766-773.
73. Benjamin S, Seek A, Tresise L, et al. Case study: paradoxical response to naltrexone treatment of self-injurious behavior. J Am Acad Child Psychiatry. 1995;34(2):238-242.
74. Willemsen-Swinkels SH, Buitelaar JK, Weijnen FG, et al. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res. 1995;58(3):203-215.
75. Pettinati HM, Weiss RD, Miller WR, et al. Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence: NIAAA COMBINE Monograph Series, Vol. 2. Bethesda, MD: Department of Health and Human Services; 2004. DHHS Publication No. 04-5289.
76. Pettinati HM, Weiss RD, Dundon W, et al. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol. 2005;suppl 15:170-178.
77. Volpicelli JR, Pettinati HM, McLellan AT, et al. Combining Medication and Psychosocial Treatments for Addictions: The BRENDA Approach. New York: Guilford Press; 2001.
78. Weiss RD. Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction. 2004;99(11):1382-1392.
79. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617-1625.
80. Kranzler HR, Modesto-Lowe V, Nuwayser ES. Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res. 1998;25:1335-1341.
81. Kranzler HR, Wesson DR, Billot L, for the Drug Abuse Sciences Naltrexone Depot Study Group. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004;28(7):1051-1059.
82. Kranzler HR, Armeli S, Tennen H, et al. Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol. 2003;23(3):294-304.
83. Allen JP, Litten RZ, Strid N, et al. The role of biomarkers in alcoholism medication trials. Alcohol Clin Exp Res. 2001;25:1119-1125.
84. Gastpar M, Bonnet U, Boning J, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol. 2002;22(6):592-598.
85. Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res. 1994;18:1162-1167.
86. Oslin DW, Liberto JG, O'Brien J, et al. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry. 1997;5:324-332.
87. Hersh D, Van kirk JR, Kranzler HR. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology. 1998;139(1-2):44-52.
88. Anton RF, Moak DH, Waid LR, et al. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156(11):1758-1764.
89. Mason BJ, Salvato FR, Williams LD, et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56:719-724.
90. Kranzler HR, Modesto-Lowe V, Van Kirk J. Nalrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology. 2000;22(5):493-503.
91. Heinala P, Alho H, Kiianmaa K, et al. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2001;21(3):287-292.
92. Lee A, Tan S, Lim D, et al. Naltrexone in the treatment of male alcoholics - an effectiveness study in Singapore. Drug Alcohol Rev. 2001;20:193-199.
93. Morris P, Hopwood M, Whelan G, et al. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 2001;96:1565-1573.
94. Ahmadi J, Ahmadi N. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence. German J Psychiatry. 2002;5(4):85-89.
95. Guardia J, Caso C, Arias F, et al. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multi-center clinical trial. Alcohol Clin Exp Res. 2002;26(9):1381-1387.
96. Latt NC, Jurd S, Houseman J, et al. Naltrexone in alcohol dependence: a randomized controlled trial of effectiveness in a standard clinical setting. Med J Aust. 2002;176(11):530-534.
97. Balldin J, Berglund M, Borg S, et al. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res. 2003;27(7):1142-1149.
98. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism. Arch Gen Psychiatry. 2003;60:92-99.
99. Anton RF, Pettinati HM, Zweben A, et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol. 2004;24(4):421-428.
100. Killeen TK, Brady KT, Gold PB, et al. Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res. 2004;28(11):1710-1717.
101. Sinclair JD. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol. 2001;36(1):2-10.
102. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revised. Washington, DC: American Psychiatric Association; 2000.
103. Brown TG, Serganian P, Tremblay J. Alcohol and cocaine abusers 6 months after traditional treatment: do they fare as well as problem drinkers? J Subst Abuse Treat. 1993;10:545-552.
104. Brower KJ, Blow FC, Hill EM, et al. Treatment outcome of alcoholics with and without cocaine disorders. Alcohol Clin Exp Res. 1994;18(3):734-739.
105. Oslin DW. Treatment of late-life depression complicated by alcohol dependence. Am J Geriatr Psychiatry. 2005;13(6):491-500.
106. Pettinati HM. Antidepressant treatment of co-occurring depression and alcohol dependence. Biol Psychiatry. 2004;56:785-792.
107. Thase M. Issues and ethics. Paper presented at: Annual American College of Neuropsychopharmacology Annual Meeting; 2003; San Juan, Puerto Rico.